Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Amyotrophic Lateral Sclerosis
... at a CAGR of 19.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$345.9 Million While China is Forecast to Grow at 18.4% CAGR The Amyotrophic Lateral Sclerosis market in the U.S. ... Read More
-
Cushing`s Syndrome Diagnostics and Treatment
... Million by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Cushing`s Syndrome Treatment, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$473.9 ... Read More
-
Leukemia Therapeutics
... CAGR of 5.6% over the analysis period 2024-2030. Chronic Myeloid Leukemia, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$9.1 Billion by the end of the ... Read More
-
Lupus Therapeutics
... CAGR of 8.7% over the analysis period 2024-2030. Anti-Inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$2.7 Billion by the end of the analysis ... Read More
-
Myasthenia Gravis Drugs
... at a CAGR of 6.6% over the analysis period 2024-2030. Drug Treatment, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of ... Read More
-
Oligonucleotide Therapeutics
... CAGR of 8.7% over the analysis period 2024-2030. Antisense / RNAI Oligonucleotides, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$4.0 Billion by the end of ... Read More
-
Diabetic Macular Edema Treatment
... 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Anti-VEGF, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$2.7 Billion by the end ... Read More
-
Microbiome Therapeutics
... CAGR of 56.8% over the analysis period 2024-2030. C. Difficile Infection, one of the segments analyzed in the report, is expected to record a 53.0% CAGR and reach US$7.3 Billion by the end of the ... Read More
-
Protein Therapeutics
... CAGR of 5.8% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$284.7 Billion by the end of the analysis ... Read More
-
Systemic Psoriasis Therapeutics
... at a CAGR of 8.1% over the analysis period 2024-2030. TNF Inhibitors, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$18.5 Billion by the end of ... Read More
-
Post-Traumatic Stress Disorder (PTSD) Therapeutics
... Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$2.1 Billion by ... Read More
-
Schizophrenia Therapeutics
... CAGR of 4.2% over the analysis period 2024-2030. Second Generation Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$7.7 Billion by the end of ... Read More
-
Systemic Lupus Erythematosus (Sle) Drugs
... Million by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$68.0 Million While China is Forecast to Grow at 6.1% CAGR The Systemic Lupus Erythematosus ... Read More
-
Alpha 1 Antitrypsin Deficiency Treatment
... Billion by 2030, growing at a CAGR of 9.0% over the analysis period 2024-2030. Augmentation Therapy, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$2.0 Billion ... Read More
-
Krabbe Disease Treatment
... at a CAGR of 6.2% over the analysis period 2024-2030. Anticonvulsants, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$823.5 Million by the end of the ... Read More
-
Protein Detection & Quantification Market Report by Product (Kits and Reagents/Consumables, Instruments, Services), Technology (Colorimetric Assays, Immunological Methods, Chromatography, Mass Spectrometry, Spectroscopy Instruments, and Others), Application (Drug Discovery and Development, Clinical Diagnosis, and Others), End User (Academic Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Research Organization, and Others), and Region 2025-2033
... during 2025-2033. The market is experiencing steady growth driven by the increasing emphasis on personalized medicine, rising need for proteomics research to uncover novel insights into protein functions, interactions, and post-translational modifications and the escalating ... Read More
-
Sickle Cell Disease (SCD) - Market Insight, Epidemiology, and Market Forecast - 2034
... with African, Middle Eastern, Mediterranean, and South Asian ancestry. The primary cause of SCD is a mutation in the HBB gene, which affects the production of hemoglobin. Individuals with SCD inherit two copies of the ... Read More
-
Idiopathic Inflammatory Myositis - Market Insights, Epidemiology, and Market Forecast - 2034
... and the UK accounted for nearly 38% and Japan represented 14% of the cases, respectively. The idiopathic inflammatory myositis market is poised for rapid growth, with a strong compound annual growth rate (CAGR) projected from ... Read More
-
Ulcerative Colitis - Market Insight, Epidemiology, and Market Forecast - 2034
... and raised awareness. Ulcerative Colitis treatment is complex and comprises the use of medication, alterations in diet and nutrition, and at times surgical procedures to repair or remove affected portions of the patient’s gastrointestinal tract. ... Read More
-
5-HT2 Antagonist - Pipeline Insight, 2025
... for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental Stages Clinical ... Read More
-
5-HT2B Antagonist - Pipeline Insight, 2025
... for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental Stages Clinical ... Read More
-
Adenosine A2B Receptor Antagonist - Pipeline Insight, 2025
... of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the ... Read More
-
Alpha 4 Beta 7 (A4b7) Integrin Inhibitor- - Pipeline Insight, 2025
... development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule ... Read More
-
Androgen Antagonist - Pipeline Insight, 2025
... for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental Stages Clinical ... Read More
-
Angiotensin Converting Enzyme (ACE) Inhibitor - Pipeline Insight, 2025
... detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered ... Read More
Research Assistance
